Mavacoxib

Mavacoxib

Mavacoxib

Veterinary drug

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.[1] It acts as a COX-2 inhibitor.[2]

Quick Facts Clinical data, Trade names ...

Mavacoxib, along with other COX-2 selective inhibitors, celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[3][4]

References

  1. [1]
    European Public Assessment Report (EPAR): Trocoxil, European Medicines Agency
  2. [2]
    Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.
  3. [3]
    Langreth R (June 23, 2003). "The Chemical Cobbler". Forbes.
  4. [4]
    "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.
Stub icon

This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Mavacoxib, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.